• June 3-6, 2024
  • San Diego Convention Center, California


Elliott Gruskin

Elliott A Gruskin, PhD

Azome Therapeutics, Inc
Elliott Gruskin is a global pharmaceutical operating executive with expertise in transforming innovative research concepts into commercial opportunities. Most recently, he served as Executive Director, Research, Strategy & Innovation at Mallinckrodt Pharmaceuticals. Prior to joining Mallinckrodt, Dr. Gruskin spent more than a decade with DePuy Synthes in the Biomaterials Division, as Global Vice President of R&D and then Worldwide President. In that role, he led an organization with over 200 employees with R&D and manufacturing sites in the US and Switzerland. During his tenure, the Biomaterials portfolio enjoyed double digit growth with $350 M in topline sales. Following the acquisition of Synthes by J&J in 2012, he became Worldwide President of DePuy Synthes Biomaterials before being appointed Global Lead for External Innovation and Enabling Technologies in Biomaterials. Dr. Gruskin received a BS in Biochemistry with High Distinction in Research from the University of Rochester and a PhD in Biochemistry from Vanderbilt University where he was a Chemical Industry Institute of Toxicology Predoctoral Fellow and a Harold Sterling Vanderbilt Scholar. He completed Post-doctoral training in the Department of Biology at the Massachusetts Institute of Technology. He began his pharmaceutical career with United State Surgical Corporation (now Covidien).
Speaking In


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.